Volume 9, Number 12—December 2003
Research
Multidrug-resistant Mycobacterium tuberculosis in HIV-Infected Persons, Peru
Pablo E. Campos*†, Pedro G. Suarez‡§, Jorge Sanchez†, David Zavala‡, Jorge Arevalo‡, Eduardo Ticona‡, Charles M. Nolan*¶, Thomas M. Hooton*, and King K. Holmes*
Table 2
Drug-susceptibility profiles of Mycobacterium tuberculosis isolates from participants with and without known HIV infectiona
| Characteristic | HIV positive |
HIV negative or unknown status |
|
|---|---|---|---|
| Patients |
Interviewed patients |
All patients |
|
| N (%) | N (%) | N (%) | |
| Total no. tested for drug resistance |
81 (100) |
108 (100) |
965 (100) |
| Fully susceptible isolates |
28 (35) |
92 (85) |
789 (82) |
| Any resistance |
52 (65) |
16 (15) |
76 (18) |
| Any H resistance |
42 (52) |
11 (10) |
110 (10) |
| Any R resistance |
39 (48) |
2 (2) |
53 (6) |
| Any E resistance |
19 (24) |
0 (0) |
27 (3) |
| Any S resistance |
39 (48) |
12 (11) |
88 (9) |
| Any Z resistance |
28 (35) |
NA |
NA |
| Multidrug resistance |
35 (43) |
1 (1) |
38 (3.9) |
| Only HR resistance |
3 (4) |
NA |
NA |
| HRZ resistance |
25 (32) |
NA |
NA |
| HRESZ resistance | 11 (14) | NA | NA |
aNA, not available; H, isoniazid; R, rifampin; E, ethambutol; S, streptomycin; Z, pyrazinamide; HRZ resistance includes any strain resistant at least to H and R and Z.
